Sulfonylureas are a class of oral medications used to lower blood sugar in people with type 2 diabetes. They work by stimulating the pancreas to release more insulin, and they’ve been in clinical use for decades. While newer drug classes have shifted their role in treatment guidelines, sulfonylureas remain among the most commonly prescribed diabetes medications worldwide, largely because they’re effective and inexpensive.
How Sulfonylureas Lower Blood Sugar
Sulfonylureas target insulin-producing beta cells in the pancreas. These cells have a specific channel on their surface that acts like a gate, opening and closing in response to energy levels inside the cell. Under normal conditions, when blood sugar rises after a meal, these channels close on their own, triggering a chain of events that ends with insulin being released into the bloodstream.
Sulfonylureas essentially force that gate shut, regardless of what’s happening with blood sugar. They bind directly to a component of the channel and lock it closed, which prompts the beta cell to release insulin. This is a powerful mechanism, but it also explains the drug’s main drawback: because insulin release isn’t tied to how much sugar is actually in your blood, there’s a real risk of your blood sugar dropping too low.
Types of Sulfonylureas
Sulfonylureas come in two generations. The first-generation drugs (like chlorpropamide and tolbutamide) are rarely prescribed today. Second-generation sulfonylureas have largely replaced them because they’re more potent, require lower doses, and can typically be taken once a day. The four second-generation options are glyburide (also called glibenclamide), glipizide, glimepiride, and gliclazide.
These aren’t interchangeable. Glyburide is the only one that produces active metabolites, meaning your body breaks it down into byproducts that continue to lower blood sugar. Those byproducts are cleared through the kidneys, so people with reduced kidney function can accumulate them, raising the risk of dangerously low blood sugar. Glipizide, by contrast, doesn’t need dose adjustments even in moderate to severe kidney disease, making it a safer choice for people with kidney problems. Gliclazide is generally usable down to an estimated kidney filtration rate of 30, while glimepiride requires dose reductions below 60 and becomes risky at more advanced stages of kidney disease.
How Well They Work
Sulfonylureas are effective at lowering blood sugar. A systematic review and meta-analysis found that sulfonylurea monotherapy lowered HbA1c (a measure of average blood sugar over roughly three months) by about 1.5 percentage points more than placebo. That’s a meaningful reduction, enough to move many people from poorly controlled diabetes into a healthier range.
The catch is that this effectiveness tends to fade. Within a few years of starting treatment, beta cells show signs of fatigue, and blood sugar control deteriorates. This phenomenon, called secondary failure, happens because the constant stimulation eventually wears out the insulin-producing cells. Over time, most people on sulfonylureas alone will need additional medications or insulin to maintain acceptable blood sugar levels.
Side Effects: Weight Gain and Low Blood Sugar
The two most significant side effects are hypoglycemia (low blood sugar) and weight gain. Sulfonylureas carry the highest risk of severe hypoglycemia among all available type 2 diabetes therapies. Because the drug pushes insulin release regardless of your actual blood sugar level, skipping a meal or exercising more than usual can cause your blood sugar to drop to dangerous levels. Symptoms of hypoglycemia include shakiness, sweating, confusion, dizziness, and in severe cases, loss of consciousness.
Weight gain is also common. Meta-analyses show that sulfonylureas are associated with a gain of roughly 2 to 2.3 kilograms (about 4 to 5 pounds) compared to placebo when added to other diabetes medications. This is particularly problematic because most people with type 2 diabetes are already managing excess weight, and the added pounds can worsen insulin resistance over time.
Alcohol and Sulfonylureas
Drinking alcohol while taking certain sulfonylureas can trigger an unpleasant reaction. Chlorpropamide (a first-generation drug) and tolbutamide are known to interfere with how your body processes alcohol, causing a buildup of a toxic byproduct called acetaldehyde. The result can include facial flushing, nausea, and a rapid heartbeat, similar to the reaction caused by the alcohol-deterrent drug disulfiram. Chlorpropamide produces the strongest effect, raising acetaldehyde levels up to 20 times above normal in animal studies. Beyond this specific reaction, alcohol on its own can lower blood sugar, compounding the hypoglycemia risk that sulfonylureas already carry.
When to Take Them
The traditional advice is to take sulfonylureas 30 minutes before a meal so the drug reaches effective levels in your blood by the time food arrives. In practice, the evidence supporting this specific timing window is limited, and some researchers have argued that strict 30-minutes-before-meal dosing may increase hypoglycemia risk and make it harder to stick with the medication consistently. Many people take their sulfonylurea with or just before a meal. What matters most is consistency and not skipping meals after taking the medication, since the drug will release insulin whether food is coming or not.
Where Sulfonylureas Fit in Treatment Today
Sulfonylureas are no longer first-line therapy for most people with type 2 diabetes. Current guidelines from the American Diabetes Association position metformin as the most common starting medication, noting that compared to sulfonylureas, metformin doesn’t cause hypoglycemia, doesn’t promote weight gain, and is associated with lower cardiovascular mortality.
The ADA’s current standards are blunt about sulfonylureas’ limitations: they recommend that use of sulfonylureas “should be limited or discontinued” because these medications don’t provide the cardiovascular, kidney, weight, or liver benefits seen with newer drug classes like GLP-1 receptor agonists and SGLT2 inhibitors. The large GRADE trial, which compared several add-on treatments to metformin, found that severe hypoglycemia was significantly more common in people taking glimepiride compared to some alternatives.
That said, sulfonylureas still have a role. They cost a fraction of what newer diabetes drugs do, they’re available generically everywhere, and they reliably lower blood sugar. For people whose primary barrier to treatment is cost, or in healthcare settings where newer medications aren’t accessible, sulfonylureas remain a practical and effective option. When they are prescribed alongside other medications, guidelines recommend using the lowest effective dose and reassessing regularly to minimize hypoglycemia risk.